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Abstract
Introduction: Non-invasive ventilation may improve autonomic modulation and
ventilatory parameters in severely disabled patients. The aim of the present
study was to evaluate the physiological influence of acute treatment with
different levels of continuous positive airway pressure (CPAP) on the autonomic
balance of heart and respiratory responses in patients with stable chronic
obstructive pulmonary disease (COPD) and chronic heart failure (CHF).
Material and methods: A COPD group (n = 10), CHF group (n = 8) and healthy
subjects (n = 10) were evaluated. The participants were randomized to receive
three different levels of CPAP on the same day: sham ventilation (Sham), 
5 cmH20 (CPAP5) and 10 cmH20 (CPAP10) for 10 min. Respiratory rate, end tidal
carbon dioxide (ETCO2), peripheral oxygen saturation (SpO2), heart rate (HR),
blood pressure and heart rate variability in the time and frequency domains
were measured during spontaneous breathing and under the sham, CPAP5 and
CPAP10 conditions.
Results: All groups experienced a reduction in ETCO2 values during treatment
with CPAP (p < 0.05). CPAP increased SpO2 and HR in the COPD group (p < 0.05).
The COPD group also had lower RMSSD values during treatment with different
levels of CPAP when compared to the control group (p < 0.05). In the CHF group,
CPAP5 and CPAP10 increased the SDNN value (p < 0.05). CPAP10 reduced the
SDNN value in the COPD group (p < 0.05).
Conclusion: The findings suggest that CPAP may cause improvements in the
neural control of heart rate in patients with stable COPD and CHF. For each
patient, the “best CPAP level” should be defined as the best respiratory response
and autonomic balance.
Key words: autonomic nervous system, cardiomyopathy, COPD, CPAP ventilation,
non-invasive ventilation.
Introduction
Autonomic tone is the balance between sympathetic and
parasympathetic activity and is responsible for controlling blood pressure
(BP), heart rate (HR), heart contractility, ventricular filling time and vascular
tone [1]. Autonomic dysfunction increases sympathetic activity and reduces
parasympathetic activity, which is related to the physiopathology of some
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diseases, arrhythmia and an elevated risk of
mortality [2, 3]. 
The determination of autonomic balance
through an analysis of R-R intervals offers a simple,
non-invasive measure of this component of
cardiovascular control. The intrinsic regulation and
control of the electrical activity of the heart rate 
can be modulated by the sympathetic and
parasympathetic nervous systems, baroreflex
activity, intrinsic cardiac nervous system,
cardiopulmonary reflexes and respiration [1].
Alterations in alveolar and intrathoracic pressure
and the activity of lung receptors during non-
invasive ventilation (NIV) could modulate the
balance of autonomic heart rate control [1]. NIV has
been used in the treatment of chronic obstructive
pulmonary disease (COPD), obstructive sleep
apnoea, chronic heart failure (CHF) and asthma 
[4-8]. Fietze et al. and Garet et al. employed different
NIV modalities and found significant changes in
intrathoracic haemodynamics, vagal efferent activity
and HR in healthy individuals [9, 10].
Different modes of continuous positive airway
pressure (CPAP) have been related to changes in
the activity of the sympathetic nervous system,
such as an increase in sympathetic nerve firing in
patients with CHF and the parasympathetic activity,
improved short and long-term haemodynamic
function, electrical remodelling, reduced respiratory
muscle work and neurohormonal modulation [7, 11-
14]. Despite the many studies demonstrating the
benefits of NIV, the effects of treatment with CPAP
on the autonomic heart rate in patients with CHF
need to be understood better.
Patients with COPD also exhibit sympathovagal
imbalance of the autonomic heart rate, which has
been related to an elevated risk of cardiovascular
events [4, 15-17]. NIV has been used as an adjunct
to COPD rehabilitation, as it increases ventilation,
allows the respiratory muscles to unload during rest
and physical exercise, and reduces symptoms of
dyspnoea [18-23]. It has been demonstrated that
bi-level positive air pressure ventilation in patients
with stable COPD may reduce end tidal carbon
dioxide (ETCO2) and HR and increase peripheral
oxygen saturation (SpO2) [4].
Neme et al. evaluated acute treatment with
different CPAP levels in patients with stable COPD
and found an improvement in ventilation and
respiratory mechanics [24]. Although treatment
with different modes of NIV has been used and
considered effective for improvement in ventilatory
mechanics, autonomic modulation and quality of
life in patients with COPD, the effect of different
CPAP levels on the autonomic control of heart rate
in patients with stable COPD remains unclear [25].
The hypothesis of the present study was that
acute treatment with CPAP would have an effect
on autonomic balance and respiratory function and
the effects of CPAP treatment on heart rate
variability (HRV) would be closely related to the
levels applied. Thus, the aim of this study was to
investigate autonomic modulation in patients with
COPD and CHF submitted to acute treatment with
different levels of CPAP .
Material and methods
Study population
The procedures used in this study were in
accordance with the recommendations of the
Helsinki Declaration [26]. All subjects provided
written informed consent before entering the study.
The protocol received approval from the Ethics
Committee of the Universidade Federal de Sa ~o
Carlos, Sa ~o Paulo, Brazil. After all evaluations and
procedures, a total of 28 male patients were divided
into three groups: 10 patients with COPD, 8 patients
with CHF and 10 healthy controls. All patients were
submitted to the following evaluations: clinical and
laboratory examinations, classification of dyspnoea,
New York Heart Association (NYHA) functional
classification, pulmonary function tests and
electrocardiography (ECG).
The following were the inclusion criteria for the
COPD group: diagnosis from a physician; forced
expiratory volume in one second (FEV1) / forced vital
capacity (FVC) ratio < 0.7 and FEV1 < 60% of
predicted; clinical stability for at least three months;
absence of current smoking habit; dyspnoea during
low and medium physical effort; and dyspnoea
during daily activities (Medical Research Council
score of I-III). The following were the inclusion
criteria for the CHF group: diagnosis from
a physician; echocardiogram with left ventricular
ejection fraction < 50%; NYHA classification score
of I-III; FEV1/FVC > 70% and FEV1 > 70% of
predicted. The control group was made up of
healthy, sedentary individuals, as determined by
the clinical classification of the American Heart
Association [29]. Patients receiving medications are
described in Table I.
Design and procedures
A double-blinded, randomized, cross-sectional
study was carried out. R-R intervals (R-Ri) and
physiological variables were collected for 10 min
during spontaneous breathing and with three CPAP
levels: sham ventilation (Sham), 5 cmH20 (CPAP5)
and 10 cmH20 (CPAP10). 
Measurements
Lung function
Spirometric tests were performed using
a portable spirometer (Hand Held 2120, Vitalograph,Arch Med Sci 5, October / 2010 721
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Ennis, Ireland). FEV1 and maximal voluntary
ventilation were determined and compared to
predicted normal values following methods
described elsewhere [21, 30].
Non-invasive ventilation protocol
Mechanical ventilatory assistance was delivered
using a CPAP device (Breas PV101, Sweden) and
administered through a comfortably fitting face
mask (Respironics, Murrysville, PA, USA). NIV was
randomized and set individually for each patient in
the following manner: Sham – breathing at minimal
pressure to experience resistance from the
equipment; CPAP5 – breathing at 5 cmH2O of
positive pressure; CPAP10 – breathing at 10 cmH2O
of positive pressure. The capnometer was attached
to the orifice in the nasal mask (BCI-1050,
Waukesha, USA). During NIV, the subjects were
instructed to relax, breathe calmly and maintain
a respiratory rate similar to spontaneous breathing
during CPAP ventilation, which was visually
displayed by the capnometer located in clear view
directly in front of the subjects. There was an initial
adaptation period (30 min) for the first randomized
CPAP level. After this period, physiological and 
HRV parameters were recorded during 10 min. 
A 10-minute rest period was given between other
randomized settings. 
Physiological measurements
SpO2 was continuously monitored using portable
pulse oximetry (Oxifast, Takaoka, Brazil). ETCO2 and
respiratory rate (RR) were determined using
a capnometer and recorded every 10 seconds as
Variable CG (n = 10) CHF (n = 8) COPD (n = 10)
Anthropometric characteristics
Age [years] 64 ±5 62 ±8 69 ±9
Height [m] 1.71 ±0.05 1.66 ±0.07 1.67 ±8.96
Weight [kg] 74 ±6 69 ±10 64 ±8*
BMI [kg/m2] 25 ±1 24 ±3 23 ±3
Lung function
FEV1 (% predicted) 91 ±20.0 81 ±9.1 40 ±10.9*
FEV1/CVF 101 ±7.0 82 ±4.2 58 ±11.8*
MRC / NYHA class
I 11
II 43
III 36
Echocardiogram
Left ventricular ejection fraction [%] 39 ±9
Cause of heart failure
Ischaemic dilated cardiomyopathy 3
Idiopathic/non-ischaemic dilated cardiomyopathy 5
Medications, n (%)
Bronchodilators 10 (100)
Beta-blockers 8 (100)
Digoxin 5 (62.5)
Nitrates 2 (25)
Angiotensin-converting enzyme inhibitors 7 (87.5)
Furosemide, n (%) 3 (37.5)
Acetylsalicylic acid, n (%) 2 (25)
Data are presented as mean ± SD
MRC denotes classification of dyspnoea; NYHA denotes functional classification of New York Heart Association
* Significant inter-group differences between COPD group vs. CG
Table I. Anthropometric characteristics, lung function, MRC and NYHA class, echocardiography, cause of heart failure
and medications in control group (CG), chronic heart failure (CHF) group and chronic obstructive pulmonary disease
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Figure 1. Flowchart – sample loss of each studied group
n = 81
CHF (n= 31) Control group (n = 26) COPD (n = 24)
CHF (n= 8) Control group (n = 10) COPD (n = 10)
Excluded:
• refused to participate 
(n = 2)
• arterial blood hypertension 
(n = 4)
• sudden weight loss and
suspicion of neoplasia 
(n = 2)
• alcoholic (n = 1)
• limited mobility due to severe
dyspnea (n = 1)
• cigarette smoker (n = 3)
• abandoned the treatment 
(n = 1)
Excluded:
• refused to participate (n = 5)
• had no echocardiography 
(n = 6)
• had multifocal ventricular
arrhythmias that compromised
the data collection (n = 3)
• recent hospitalization (n = 2)
• more than three months of
cardiac rehabilitation program
(n = 2)
• demand pacemaker (n = 1)
• unstable angina during
incremental symptom-limited
exercise test (n = 1)
• cigarette smoker (n = 1)
• abandoned the treatment 
(n = 1)
• death (n = 1)
Excluded:
• refused to participate (n = 2)
• physically active (n = 7)
• arterial blood hypertension 
(n = 5)
• previous history of asthma 
(n = 1)
• knee osteoarthritis and
limiting pain during the
incremental symptom-limited
exercise test (n = 1)
well as at the end of the procedures. Systolic blood
pressure (SBP) and diastolic blood pressure (DBP)
were measured using an indirect method and were
analysed at baseline as well as during the last 30 s
of the protocol. HRV was recorded using the Polar
system (S810i). The digitally coded R-Ri length was
continuously transferred to the Polar Precision
Performance software, which displays an HR
tachogram on the monitor. Patients were also
monitored using a thoracic MC5 lead (cardiac
monitor Ecafix TC500, Sa ~o Paulo, SP, Brazil) to
simultaneously obtain the HR in order to evaluate
the signals on the monitor to exclude movement
artefacts and ectopic beats prior to the HRV analysis.
HRV analysis
For the HRV analysis, the most stable sections
containing 256 points within the 10 min were
selected. HRV was analysed in the time (RMSSD –
the square root of the sum of the squares of the
differences between adjacent normal to normal
intervals; and SDNN – the standard deviation of
normal to normal intervals) and frequency domains
[31, 32]. Absolute and normalized units and
low/high frequency ratios were also calculated [3].
Statistical analysis
The data are presented as mean ± SD after
testing for normal distribution (Kolmogorov-
Smirnov). The sample size was calculated using the
GraphPad StatMate software, version 1.01. Based
on a pilot study, the target number of patients was
calculated to be 10 in each group, with a 5% 
type I error, a 2-sided test and 90% power to detect
a 5% change in ETCO2 between spontaneous
breathing and the different CPAP levels. These
calculations were based on the mean ETCO2
difference required for clinical significance. Inter-
group differences were evaluated using one-way
analysis of variance (ANOVA) with Tukey’s post-hoc
test. The level of significance was set at 5%. The
analysis was carried out using the Statistical
Package for the Social Sciences.
Results
Figure 1 shows the sample loss of each studied
group. Table I displays the mean values of the
demographic and anthropometric characteristics of
the sample, pulmonary function, classification of
dyspnoea, echocardiogram, cause of heart failure
and medications used in the CHF and COPD groups.Arch Med Sci 5, October / 2010 723
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No significant differences were found between
groups regarding age, height and body mass index
(BMI). However, the COPD group had a significantly
lower body mass when compared to the control
group. As expected, patients with COPD had
moderate-to-severe forms of the disease [28].
Effects of CPAP on physiological variables
No significant intra-group differences were found
in RR between spontaneous breathing and the
different CPAP levels in the control and CHF groups.
However, a significant reduction in RR was found
in the COPD group with all different CPAP levels
when compared to spontaneous breathing 
(p < 0.05). Moreover, RR during spontaneous
breathing was higher in the COPD group 
when compared to the control group (p < 0.05).
A significant reduction in ETCO2 was found during
treatment with CPAP in all groups. In the COPD
group, higher CPAP levels led to a greater reduction
in ETCO2. In the CHF group, a significant reduction
only occurred in the treatment with CPAP 10 cmH2O
when compared to spontaneous breathing and
sham CPAP (Table II). A significant increase in SpO2
was found in the COPD group during treatment
with the different CPAP levels when compared to
spontaneous breathing. Moreover, SpO2 in the
COPD group was significantly lower than that in the
control and CHF groups under all conditions 
(Table II). In the intra-group comparisons,
a significant reduction in DBP was found during the
sham CPAP and CPAP5 in the control group alone.
Significantly lower SBP values in the CHF group
were found during spontaneous breathing, sham
CPAP and CPAP10 when compared to the control
and COPD groups (Table II).
Effects of CPAP on HRV
A significant increase in HR occurred during
treatment with sham CPAP and 5 cmH2O compared
to spontaneous breathing in the COPD group. During
treatment with CPAP 5 and 10 cmH2O, higher HR
values were found in the COPD group when
compared to the CHF group (Table III). In the time
domain, significantly lower RMSSD values during
treatment with different CPAP levels when compared
to spontaneous breathing were found in the COPD
group alone (Figure 2). Moreover, significantly lower
RMSSD values were found during treatment with
different CPAP levels in the COPD group when
compared to the control group (Table III). In the CHF
group, significant increases in SDNN and power
spectral density were found during treatment with
CPAP 5 and 10 cmH2O when compared to
spontaneous breathing (Figure 2). In the inter-group
comparisons, lower SDNN values were found in the
COPD group during treatment with CPAP 10 cmH2O
when compared to the control group (Table III). 
No significant intra-group differences in R-Ri values
were found during treatment with the different CPAP
levels when compared to spontaneous breathing.
In the inter-group comparisons, higher R-Ri values
during treatment with the different CPAP levels were
found in the COPD group when compared to the
control group.
Discussion
The important novel finding of the present study
is that treatment with higher CPAP levels induced
greater adjustment in autonomic function in
patients with COPD and CHF. CPAP 5 cmH2O led to
an improvement in ventilation with no imbalance
in autonomic heart rate modulation in patients with
COPD. However, acute treatment with CPAP10
altered autonomic regulation, leading to an increase
in sympathetic activity and a reduction in
parasympathetic activity in patients with COPD.
Moreover, the best responses in ventilation and
autonomic balance in patients with CHF seem to
be with CPAP10.
Variable CG (n = 10) CHF (n = 8) COPD (n = 10)
SB Sham CPAP5 CPAP10 SB Sham CPAP5 CPAP10 SB Sham CPAP5 CPAP10
RR [bpm] 12 ±3* 12 ±2 13 ±3 13 ±3 15 ±2 13 ±3 13 ±3 13 ±3 18 ±4 14 ±4a 15 ±3a 14 ±3a
ETCO2 [cmH2O] 38 ±4 35 ±4a 31 ±6a 30 ±5a,c 38 ±3 35 ±5 31 ±6 31 ±6a,c 35 ±5 32 ±5a 29 ±5a,b 27 ±6a,c,d
SpO2 [%] 97 ±1* 97±1* 97 ±1* 97 ±1* 96 ±2† 97 ±1† 97 ±1† 97 ±1† 92 ±3 94 ±2a 94 ±2a 95 ±3a
SBP [mmHg] 120 ±8‡ 117 ±9*‡ 117 ±9 118 ±7*‡ 106 ±13† 106 ±9† 107 ±8 107 ±7† 120 ±7 118 ±9 116 ±9 117 ±8
DBP [mmHg] 78 ±4 74 ±7a 74 ±7a 76 ±5 71 ±10 71 ±8 70 ±9 69 ±9 72 ±8 72 ±8 73 ±8 74 ±8
Data are presented as mean ± SD, Sham – breathing at 3 cmH2O, CPAP5 – breathing at 5 cmH2O positive pressure, CPAP10 – breathing at 
10 cmH2O positive pressure, RR – respiratory rate, ETCO2 – end tidal carbon dioxide, SpO2 – peripheral oxygen saturation, SBP – systolic blood
pressure, DBP – diastolic blood pressure, asignificant intra-group differences compared to SB, bsignificant intra-group differences between
Sham and CPAP5, csignificant intra-group differences between Sham and CPAP10, dsignificant intra-group differences between CPAP10 and
CPAP5, *significant inter-group differences between COPD group and CG, ‡significant inter-group differences between CHF group and CG, 
†significant inter-group differences between COPD and CHF groups
Table II. Physiological variables in control group (CG), chronic heart failure (CHF) group and chronic obstructive
pulmonary disease (COPD) group during spontaneous breathing (SB) and different CPAP levels724 Arch Med Sci 5, October / 2010
These findings indicate the presence of a “best
CPAP level” in the short-term administration of non-
invasive CPAP acting on the modulation of
autonomic tone and respiratory responses. New
strategies and careful titration for finding the ‘best
CPAP level’ for individual patients is very important,
as patients with COPD and CHF have autonomic
heart dysfunction related to an increased risk of
cardiovascular events and mortality [7, 15].
Effects of CPAP on ventilatory parameters and
autonomic balance of HR
Patients with COPD and CHF have a considerable
reduction in lung function, which exacerbates the
impact of the illness [33, 34]. Acute CPAP treatment
in patients with stable COPD reduces symptoms of
dyspnoea as well as RR and ETCO2 values. In COPD,
the respiratory system is primarily hampered by the
additional elastic load associated with dynamic
hyperinflation and intrinsic positive end-expiratory
pressure (PEEP). These factors predispose patients
to respiratory failure by increasing the load on the
respiratory muscles, while decreasing their
mechanical efficiency and capacity for generating
maximal pressure [35].
In the present study, CPAP likely reduced the
respiratory load imposed by intrinsic PEEP . When
proximal airway pressure is elevated by CPAP to
a level approaching the intrinsic PEEP, the
inspiratory muscles only need to lower alveolar
pressure to the CPAP level to initiate inspiration.
Previous studies have demonstrated that RR and
ETCO2 can modulate HRV [4, 36]. In the present
study, a significant reduction was found in the HF
band and RMSSD index, along with an increase in
the LF band during acute treatment with CPAP10 in
patients with COPD, indicating an imbalance in
autonomic control. The HF band and RMSSD
components are both generally defined as markers
of vagal modulation and the LF band has been
associated with sympathetic activity [3]. In this
autonomic adaptation, the increase in sympathetic
activity and reduction in parasympathetic activity
may not be favourable, as it has been related to
physiopathological diseases, arrhythmia and an
increased risk of mortality [2, 3]. Interestingly, when
the patients with COPD were submitted to acute
treatment with CPAP5, the same responses in
ventilatory parameters and autonomic balance
occurred, with a reduction only in the RMSSD index.
Moreover, this reduction in RMSSD was significantly
lower than that during CPAP10. These results indicate
that acute treatment with CPAP5 is safer than
CPAP10, probably due to inducing lesser imbalance
in autonomic tone in patients with stable COPD.
In the patients with CHF, acute treatment with
different levels of CPAP promoted few changes in
respiratory function and autonomic balance. During
acute treatment with CPAP5 there were no changes
in respiratory response when compared to
spontaneous breathing. However, there was
a significant increase in the SDNN index.
A reduction in this index is an independent
predictor of mortality [3, 37]. Interestingly, acute
treatment with CPAP10 caused a significant
reduction in ETCO2 and an increase in the SDNN
index at the same proportion as CPAP5. Moreover,
CPAP10 led to a significant increase in total power
of spectral density, which reflects a mixture of both
autonomic inputs [3, 12]. Based on these acute
responses, treatment with CPAP10 offers greater
advantages and safety in patients with CHF. There
is a clear association between reduced HRV and
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Figure 2. Heart rate variability during spontaneous
breathing (SB) and different CPAP levels 
asignificant intra-group differences compared to SB,
dsignificant intra-group differences between CPAP10 vs.
CPAP5, Data are presented as mean ± SD, Sham – breathing
at 3 cmH2O, CPAP5 – breathing at 5 cmH2O positive pressure,
CPAP10 – breathing at 10 cmH2O positive pressure, RMSSD
(ms) index – SDNN index
COPD group
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poor outcomes in a number of chronic and acute
heart diseases [38].
The different pressure levels administered were
enough to improve SpO2 in the patients with COPD,
whereas no changes occurred in the healthy
subjects or patients with CHF. As expected, lower
SpO2 levels at rest were found in the patients with
COPD. These conditions during walking and exercise
are a critical problem during rehabilitation [20, 39].
Moreover, CPAP has been used in the treatment of
a number of diseases, particularly COPD and
obstructive sleep apnoea [2, 39, 40].
In the present study, acute treatment with CPAP
increased SpO2 and did not alter BP in patients with
COPD. Moreover, no alterations in BP occurred in
patients with CHF during acute treatment with
CPAP . Ensuring SpO2 and maintaining BP is
favourable to haemodynamic responses. While CPAP
is effective in treating diverse acute and chronic
conditions, its benefits to BP remain unclear [40].
Treatment with different levels of CPAP did not
alter HR in any of the groups, except the COPD
group during treatment with 10 cmH2O. Although
automaticity is intrinsic to different cardiac tissues
with pacemaker properties, the HR and contractile
activity of the myocardium are largely modulated
by sympathetic and vagal outflows [1]. Acute
treatment with CPAP5 and 10 decreased the RMSSD
index in patients with COPD, which is predomi  -
nantly vagally mediated, reflected in an increase in
HR [3]. The decrease in the RMSSD component was
significantly lower during acute treatment with 
5 cmH2O.
Regarding the limitations of the present study,
it should be taken into consideration that the
patients with CHF were receiving beta-blockers and
the COPD group was using bronchodilators, which
could have influenced the outcome. However, we
intended to evaluate these patients under real-life
conditions. Additionally, more studies are necessary
HRV Index CG (n = 10) CHF (n = 8) COPD (n = 10)
SB Sham CPAP5 CPAP10 SB Sham CPAP5 CPAP10 SB Sham CPAP5 CPAP10
TD
HR  [bpm] 1.83 1.82 1.83  1.83 1.82  1.82 1.82 1.82  1.86  1.86 1.89  1.92 
±0.06 ±0.05 ±0.05* ±0.06* ±0.06 ±0.04 ±0.04† ±0.04† ±0.07 ±0.07 ±0.06 ±0.06a,c,d
R-Ri [ms] 2.95  2.95  2.96  2.95  2.94  2.91 2.91  2.90  2.92  2.89  2.89  2.88 
±0.06 ±0.05* ±0.05* ±0.06* ±0.07 ±0.04 ±0.04 ±0.03 ±0.07 ±0.07 ±0.07 ±0.06
RMSSD [ms] 1.29  1.36  1.34  1.30  1.12  1.20  1.22  1.19  1.22  1.06  1.08  1.01 
±0.14 ±0.25* ±0.15* ±0.21* ±0.10 ±0.13 ±0.14 ±0.19 ±0.17 ±0.27a ±0.25a ±0.26a,d
SDNN [ms] 1.46  1.48  1.45  1.47 1.31  1.41  1.44  1.48 1.33  1.28  1.28  1.23 
±0.13 ±0.19 ±0.16 ±0.19* ±0.06 ±0.16 ±0.09a ±0.10a ±0.18 ±0.28 ±0.33 ±0.28
FD
PSD 2.93 2.96 2.90 2.94 2.62  2.81 2.87 2.97  2.67  2.57  2.57  2.46 
±0.26 ±0.38* ±0.33* ±0.39* ±0.12 ±0.31 ±0.19a ±0.20a ±0.37 ±0.55 ±0.65 ±0.57
LF [ms2] 2.38 2.50 2.41 2.57 2.06  2.37 2.29 2.45  1.84  1.90  1.89  1.89 
±0.32* ±0.40 ±0.33 ±0.41* ±0.20 ±0.46 ±0.39 ±0.40 ±0.58 ±0.69 ±0.79 ±0.63
HF [ms2] 2.17  2.31  2.27  2.10  1.81  1.90  1.98  1.93  1.90  1.62  1.60  1.55 
±0.28 ±0.54 ±0.32 ±0.45 ±0.30 ±0.39 ±0.37 ±0.56 ±0.40 ±0.46 ±0.49 ±0.51a
LFnu 1.76 1.74 1.74  1.86 1.80  1.82 1.77 1.82  1.60  1.80 1.79  1.82 
±0.14* ±0.17 ±0.10 ±0.06a,c,d,* ±0.11 ±0.13 ±0.16 ±0.17 ±0.30 ±0.11 ±0.16 ±0.10a
HFnu 1.55 1.55  1.60 1.39  1.50  1.36 1.47  1.30  1.64  1.52  1.49  1.48 
±0.22 ±0.28 ±0.20 ±0.16 ±0.24 ±0.39 ±0.38 ±0.45 ±0.30 ±0.16 ±0.22 ±0.19
LF/HF ratio 0.21  0.19  0.14  0.47  0.26  0.47  0.30  0.52  –0.07  0.28  0.29  0.34 
±0.36 ±0.44 ±0.29 ±0.22 ±0.30 ±0.52 ±0.53 ±0.61 ±0.62 ±0.28 ±0.38 ±0.29
Data are presented as mean ± SD, Sham – breathing at 3 cmH2O, CPAP5 – breathing at 5 cmH2O positive pressure, CPAP10 – breathing at 
10 cmH2O positive pressure, HR – heart rate, R-Ri – electrocardiographic R-R intervals, RMSSD – root mean square of successive differences 
in R-R intervals in ECG, SDNN – standard deviation of normal R-R intervals in ECG, PSD – total power spectral density, LF – low frequency, 
HF – high frequency, LFnu – normalized LF units, HFnu – normalized HF units, LF/HF ratio – global sympathovagal balance, asignificant intra-
group differences compared to SB, csignificant intra-group differences between Sham and CPAP10, dsignificant intra-group differences
between CPAP10 and CPAP5, *significant inter-group differences between COPD group and CG, †significant inter-group differences between
COPD and CHF groups
Table III. Heart rate variability values in time domain (TD) and frequency domain (FD) of control group (CG), chronic
heart failure (CHF) group and chronic obstructive pulmonary disease (COPD) group during spontaneous breathing
(SB) and different CPAP levels726 Arch Med Sci 5, October / 2010
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to evaluate women under the same COPD and CHF
conditions. 
Autonomic dysfunction, an increase in sym  -
pathetic activity and a reduction in para  sympathetic
activity have been reported in patients with COPD
and CHF. These dysfunctions are associated with
physiopathological diseases, arrhythmia and an
increased risk of cardiovascular events and
mortality. CPAP has been extensively used as an
effective component during rehabilitation in this
population, as it improves ventilatory parameters,
haemodynamics and autonomic balance. The
findings of the present study reveal that treatment
with different levels of CPAP promotes different
autonomic responses. Thus, finding an individual’s
“best CPAP level” increases the safety and efficiency
of treatment.
In conclusion, these findings suggest that CPAP
may improve the neural control of heart rate in
patients with stable COPD and CHF. For each
patient, a “best CPAP level” should be defined in
association with the greatest ventilatory response
and autonomic balance. In cases in which two or
more CPAP levels resulted in a better ventilatory
response and sympathetic activity, the “best CPAP”
was the level associated with the greatest
ventilatory response and the least reduction in
parasympathetic activity.
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